{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:26:53Z","timestamp":1788910013812,"version":"build-2803163510"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research, India","doi-asserted-by":"crossref","award":["5\/4\/8-10\/Obs\/MPP\/2022-NCD\/II"],"award-info":[{"award-number":["5\/4\/8-10\/Obs\/MPP\/2022-NCD\/II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research, India","doi-asserted-by":"crossref","award":["5\/4\/8-10\/Obs\/MPP\/2022-NCD\/II"],"award-info":[{"award-number":["5\/4\/8-10\/Obs\/MPP\/2022-NCD\/II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-026-00698-4","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:50:39Z","timestamp":1773759039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MASLD In Children - A Distinct Phenotype?"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7483-0857","authenticated-orcid":false,"given":"Pervej Alom","family":"Barbhuiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9182-7948","authenticated-orcid":false,"given":"Manash Pratim","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"698_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s13668-024-00598-w","volume":"14","author":"PA Barbhuiya","year":"2025","unstructured":"Barbhuiya PA, Ahmed A, Dutta PP, Sen S, Pathak MP. Mitigating Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Role of Bioactive Phytoconstituents in Indian Culinary Spices. Curr Nutr Rep. 2025;14:20. https:\/\/doi.org\/10.1007\/s13668-024-00598-w.","journal-title":"Curr Nutr Rep"},{"key":"698_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-025-00626-y","volume":"14","author":"PA Barbhuiya","year":"2025","unstructured":"Barbhuiya PA, Yoshitomi R, Pathak MP. Understanding the Link Between Sterol Regulatory Element Binding Protein (SREBPs) and Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD). Curr Obes Rep. 2025;14:36. https:\/\/doi.org\/10.1007\/s13679-025-00626-y.","journal-title":"Curr Obes Rep"},{"key":"698_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100164","volume":"14","author":"J Panganiban","year":"2025","unstructured":"Panganiban J, Kehar M, Ibrahim SH, Hartmann P, Sood S, Hassan S, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025. Obes Pillars. 2025;14:100164. https:\/\/doi.org\/10.1016\/j.obpill.2025.100164.","journal-title":"Obes Pillars"},{"key":"698_CR4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.21037\/hbsn-23-308","volume":"12","author":"S Ciardullo","year":"2023","unstructured":"Ciardullo S, Vergani M, Ronchetti C, Perseghin G. Shaping the future of pediatric liver health: unraveling the impact of the new metabolic-associated fatty liver disease definition. Hepatobiliary Surg Nutr. 2023;12:611\u20135. https:\/\/doi.org\/10.21037\/hbsn-23-308.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"698_CR5","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:S32\u201350. https:\/\/doi.org\/10.3350\/cmh.2024.0431.","journal-title":"Clin Mol Hepatol"},{"key":"698_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54707","volume":"8","author":"P Le","year":"2025","unstructured":"Le P, Tatar M, Dasarathy S, Alkhouri N, Herman WH, Taksler GB, et al. Estimated Burden of Metabolic Dysfunction\u2013Associated Steatotic Liver Disease in US Adults, 2020 to 2050. JAMA Netw Open. 2025;8:e2454707. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.54707.","journal-title":"JAMA Netw Open"},{"key":"698_CR7","first-page":"255","volume":"21","author":"R Kohli","year":"2025","unstructured":"Kohli R. Overview of metabolic dysfunction-associated steatohepatitis in children. Gastroenterol Hepatol. 2025;21:255\u20138.","journal-title":"Gastroenterol Hepatol"},{"key":"698_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s12519-025-00902-w","volume":"21","author":"W Hathagoda","year":"2025","unstructured":"Hathagoda W, Rajindrajith S, Niriella MA. Gaps and challenges in the management of pediatric steatotic liver diseases: a narrative review. World J Pediatr. 2025;21:352\u201360. https:\/\/doi.org\/10.1007\/s12519-025-00902-w.","journal-title":"World J Pediatr"},{"key":"698_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186422","volume":"135","author":"JB Schwimmer","year":"2025","unstructured":"Schwimmer JB, Biddinger SB, Ibrahim SH. MASLD in children: integrating epidemiological trends with mechanistic and translational advances. J Clin Invest. 2025;135:e186422. https:\/\/doi.org\/10.1172\/JCI186422.","journal-title":"J Clin Invest"},{"key":"698_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.32420","volume":"7","author":"F Ebrahimi","year":"2024","unstructured":"Ebrahimi F, Yao J, Hagstr\u00f6m H, Stephansson O, Sun J, Bergman D, et al. Birth weight, gestational age, and risk of pediatric-onset MASLD. JAMA Netw Open. 2024;7:e2432420. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.32420.","journal-title":"JAMA Netw Open"},{"key":"698_CR11","doi-asserted-by":"publisher","first-page":"e70137","DOI":"10.1002\/jgh3.70137","volume":"9","author":"Y Lin","year":"2025","unstructured":"Lin Y, Liao F, Chao H, Chen A, Jeng Y, Lin C, et al. Consensus Statement on Metabolic Dysfunction-Associated Steatotic Liver Disease in Children and Adolescents From the Joint TASL \u2010 TSPGHAN Expert Committee. JGH Open. 2025;9:e70137. https:\/\/doi.org\/10.1002\/jgh3.70137.","journal-title":"JGH Open"},{"key":"698_CR12","doi-asserted-by":"publisher","unstructured":"G\u00f3mez-Mendoza R, S\u00e1nchez-Hern\u00e1ndez F, Valentin-Cortez FJ, Ch\u00e1vez-Tapia N. Fatty liver disease in the pediatric population: history, definitions, and challenges in nomenclature (NAFLD\/MAFLD\/MASLD). Metab Target Organ Damage [Internet]. 2025 [cited 2025 Aug 16];5. https:\/\/doi.org\/10.20517\/mtod.2024.108","DOI":"10.20517\/mtod.2024.108"},{"key":"698_CR13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/liv.15852","volume":"44","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Paik J, Owrangi S, Yilmaz Y, El-Kassas M, et al. Prevalence of metabolic dysfunction\u2010associated steatotic liver disease in the Middle East and North Africa. Liver Int. 2024;44:1061\u201370. https:\/\/doi.org\/10.1111\/liv.15852.","journal-title":"Liver Int"},{"key":"698_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s12519-024-00814-1","volume":"20","author":"EJ Lee","year":"2024","unstructured":"Lee EJ, Choi M, Ahn SB, Yoo J-J, Kang SH, Cho Y, et al. Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis. World J Pediatr. 2024;20:569\u201380. https:\/\/doi.org\/10.1007\/s12519-024-00814-1.","journal-title":"World J Pediatr"},{"key":"698_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12072-023-10596-9","volume":"18","author":"B Jin","year":"2024","unstructured":"Jin B, Wu Z, Wang S, Yu Z, Ullah R, Liang X, et al. Gender differences in non-alcoholic fatty liver disease in obese children and adolescents: a large cross-sectional study. Hepatol Int. 2024;18:179\u201387. https:\/\/doi.org\/10.1007\/s12072-023-10596-9.","journal-title":"Hepatol Int"},{"key":"698_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1136\/gutjnl-2023-331090","volume":"74","author":"NP Goyal","year":"2025","unstructured":"Goyal NP, Xanthakos S, Schwimmer JB. Metabolic dysfunction-associated steatotic liver disease in children. Gut. 2025;74:669\u201377. https:\/\/doi.org\/10.1136\/gutjnl-2023-331090.","journal-title":"Gut"},{"key":"698_CR17","doi-asserted-by":"publisher","first-page":"100173","DOI":"10.1016\/j.obpill.2025.100173","volume":"14","author":"E Tas","year":"2025","unstructured":"Tas E, Flint A, Libman I, Muzumdar R, Ou X, Williams DK, et al. The association between hepatic steatosis, vitamin D status, and insulin resistance in adolescents with obesity. Obes Pillars. 2025;14:100173. https:\/\/doi.org\/10.1016\/j.obpill.2025.100173.","journal-title":"Obes Pillars"},{"key":"698_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3350\/cmh.2024.0562","volume":"30","author":"JH Bae","year":"2024","unstructured":"Bae JH. Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: a call for culturally sensitive interventions: editorial on \u201cDifferences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: a longitudinal real-world study.\u201d Clin Mol Hepatol. 2024;30:665\u20138. https:\/\/doi.org\/10.3350\/cmh.2024.0562.","journal-title":"Clin Mol Hepatol"},{"key":"698_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4082\/kjfm.25.0027","volume":"46","author":"D Lorek","year":"2025","unstructured":"Lorek D, \u0141upina K, Bisaga W, Malicki D, St\u0119pie\u0144 W, Kumor L, et al. The socioeconomic and environmental determinants of metabolic dysfunction-associated steatotic liver disease: understanding inequalities in prevalence and outcomes. Korean J Fam Med. 2025;46:61\u20139. https:\/\/doi.org\/10.4082\/kjfm.25.0027.","journal-title":"Korean J Fam Med"},{"key":"698_CR20","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3945\/ajcn.2008.27416","volume":"90","author":"PM Catalano","year":"2009","unstructured":"Catalano PM, Farrell K, Thomas A, Huston-Presley L, Mencin P, De Mouzon SH, et al. Perinatal risk factors for childhood obesity and metabolic dysregulation. Am J Clin Nutr. 2009;90:1303\u201313. https:\/\/doi.org\/10.3945\/ajcn.2008.27416.","journal-title":"Am J Clin Nutr"},{"key":"698_CR21","doi-asserted-by":"publisher","first-page":"792","DOI":"10.4254\/wjh.v12.i10.792","volume":"12","author":"QC Lisboa","year":"2020","unstructured":"Lisboa QC, Nardelli MJ, Pereira PDA, Miranda DM, Ribeiro SN, Costa RSN, et al. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World J Hepatol. 2020;12:792\u2013806. https:\/\/doi.org\/10.4254\/wjh.v12.i10.792.","journal-title":"World J Hepatol"},{"key":"698_CR22","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.3748\/wjg.v28.i25.2890","volume":"28","author":"NB Wajsbrot","year":"2022","unstructured":"Wajsbrot NB, Leite NC, Salles GF, Villela-Nogueira CA. Non-alcoholic fatty liver disease and the impact of genetic, epigenetic and environmental factors in the offspring. World J Gastroenterol. 2022;28:2890\u20139. https:\/\/doi.org\/10.3748\/wjg.v28.i25.2890.","journal-title":"World J Gastroenterol"},{"key":"698_CR23","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/cpt.1701","volume":"107","author":"R Garc\u00eda-Rom\u00e1n","year":"2020","unstructured":"Garc\u00eda-Rom\u00e1n R, Franc\u00e9s R. Acetaminophen-induced liver damage in hepatic steatosis. Clin Pharmacol Ther. 2020;107:1068\u201381. https:\/\/doi.org\/10.1002\/cpt.1701.","journal-title":"Clin Pharmacol Ther"},{"key":"698_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0046-8177(90)90076-H","volume":"21","author":"JH Lewis","year":"1990","unstructured":"Lewis JH, Mullick F, Ishak KG, Ranard RC, Ragsdale B, Perse RM, et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol. 1990;21:59\u201367. https:\/\/doi.org\/10.1016\/0046-8177(90)90076-H.","journal-title":"Hum Pathol"},{"key":"698_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0168-8278(99)80020-8","volume":"30","author":"P Chariot","year":"1999","unstructured":"Chariot P, Drogou I, Lacroix-Szmania ID, Eliezer-Vanerot M-C, Chazaud B, Lomb\u00e8s A, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol. 1999;30:156\u201360. https:\/\/doi.org\/10.1016\/S0168-8278(99)80020-8.","journal-title":"J Hepatol"},{"key":"698_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0168-8278(97)80496-5","volume":"26","author":"B Fromenty","year":"1997","unstructured":"Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis effects of drugs, ethanol, hormones and cytokines. J Hepatol. 1997;26:43\u201353. https:\/\/doi.org\/10.1016\/S0168-8278(97)80496-5.","journal-title":"J Hepatol"},{"key":"698_CR27","doi-asserted-by":"publisher","first-page":"G1141","DOI":"10.1152\/ajpgi.1997.272.5.G1141","volume":"272","author":"P Letteron","year":"1997","unstructured":"Letteron P, Brahimi-Bourouina N, Robin MA, Moreau A, Feldmann G, Pessayre D. Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta-oxidation. Am J Physiol Gastrointest Liver Physiol. 1997;272:G1141-50. https:\/\/doi.org\/10.1152\/ajpgi.1997.272.5.G1141.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"698_CR28","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1309\/5HR90TNC4Q4JRXWX","volume":"121","author":"P Hytiroglou","year":"2004","unstructured":"Hytiroglou P, Tobias H, Saxena R, Abramidou M, Papadimitriou CS, Theise ND. The canals of Hering might represent a target of Methotrexate hepatic toxicity. Am J Clin Pathol. 2004;121:324\u20139. https:\/\/doi.org\/10.1309\/5HR90TNC4Q4JRXWX.","journal-title":"Am J Clin Pathol"},{"key":"698_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0022-3565(25)22933-0","volume":"255","author":"E Freneaux","year":"1990","unstructured":"Freneaux E, Fromenty B, Berson A, Labbe G, Degott C, Letteron P, et al. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial beta-oxidation of fatty acids. J Pharmacol Exp Ther. 1990;255:529\u201335.","journal-title":"J Pharmacol Exp Ther"},{"key":"698_CR30","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/hep.23813","volume":"52","author":"LK Cole","year":"2010","unstructured":"Cole LK, Jacobs RL, Vance DE. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology. 2010;52:1258\u201365. https:\/\/doi.org\/10.1002\/hep.23813.","journal-title":"Hepatology"},{"key":"698_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/hep.28283","volume":"63","author":"M Goffredo","year":"2016","unstructured":"Goffredo M, Caprio S, Feldstein AE, D\u2019Adamo E, Shaw MM, Pierpont B, et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. Hepatology. 2016;63:117\u201325. https:\/\/doi.org\/10.1002\/hep.28283.","journal-title":"Hepatology"},{"key":"698_CR32","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/hep.23832","volume":"52","author":"N Santoro","year":"2010","unstructured":"Santoro N, Kursawe R, D\u2019Adamo E, Dykas DJ, Zhang CK, Bale AE, et al. A Common Variant in the Patatin-Like Phospholipase 3 Gene (PNPLA3) Is Associated with Fatty Liver Disease in Obese Children and Adolescents. Hepatology. 2010;52:1281\u201390. https:\/\/doi.org\/10.1002\/hep.23832.","journal-title":"Hepatology"},{"key":"698_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12852","volume":"17","author":"KJ Lee","year":"2022","unstructured":"Lee KJ, Moon JS, Kim NY, Ko JS. Effects of <sc>PNPLA3<\/sc>, <sc>TM6SF2<\/sc> and <sc>SAMM50<\/sc> on the development and severity of non-alcoholic fatty liver disease in children. Pediatr Obes. 2022;17:e12852. https:\/\/doi.org\/10.1111\/ijpo.12852.","journal-title":"Pediatr Obes"},{"key":"698_CR34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000445061","volume":"9","author":"H Huvenne","year":"2016","unstructured":"Huvenne H, Dubern B, Cl\u00e9ment K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9:158\u201373. https:\/\/doi.org\/10.1159\/000445061.","journal-title":"Obes Facts"},{"key":"698_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/hep.32570","volume":"77","author":"NP Goyal","year":"2023","unstructured":"Goyal NP, Rosenthal SB, Nasamran C, Behling CA, Angeles JE, Fishbein MH, et al. Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in children. Hepatology. 2023;77:197\u2013212. https:\/\/doi.org\/10.1002\/hep.32570.","journal-title":"Hepatology"},{"key":"698_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/MED.0000000000000798","volume":"30","author":"CM Trapp","year":"2023","unstructured":"Trapp CM, Censani M. Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity. Curr Opin Endocrinol Diabetes Obes. 2023;30:136\u201340. https:\/\/doi.org\/10.1097\/MED.0000000000000798.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"698_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/MPG.0000000000000618","volume":"60","author":"PA Ugalde-Nicalo","year":"2015","unstructured":"Ugalde-Nicalo PA, Schwimmer JB. On the origin of pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2015;60:147\u20138. https:\/\/doi.org\/10.1097\/MPG.0000000000000618.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"698_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1256075","volume":"14","author":"JY Kweon","year":"2024","unstructured":"Kweon JY, Mun H, Choi MR, Kim HS, Ahn YJ. Maternal obesity induced metabolic disorders in offspring and myeloid reprogramming by epigenetic regulation. Front Endocrinol. 2024;14:1256075. https:\/\/doi.org\/10.3389\/fendo.2023.1256075.","journal-title":"Front Endocrinol"},{"key":"698_CR39","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/ajcn\/nqac168","volume":"116","author":"CC Cohen","year":"2022","unstructured":"Cohen CC, Harrall KK, Gilley SP, Perng W, Sauder KA, Scherzinger A, et al. Body composition trajectories from birth to 5 years and hepatic fat in early childhood. Am J Clin Nutr. 2022;116:1010\u20138. https:\/\/doi.org\/10.1093\/ajcn\/nqac168.","journal-title":"Am J Clin Nutr"},{"key":"698_CR40","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/hep.32540","volume":"76","author":"C Amadou","year":"2022","unstructured":"Amadou C, Nabi O, Serfaty L, Lacombe K, Boursier J, Mathurin P, et al. Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort. Hepatology. 2022;76:1438\u201351. https:\/\/doi.org\/10.1002\/hep.32540.","journal-title":"Hepatology"},{"key":"698_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jpeds.2017.03.007","volume":"187","author":"KP Newton","year":"2017","unstructured":"Newton KP, Feldman HS, Chambers CD, Wilson L, Behling C, Clark JM, et al. Low and high birth weights are risk factors for nonalcoholic fatty liver disease in children. J Pediatr. 2017;187:141-146.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2017.03.007.","journal-title":"J Pediatr"},{"key":"698_CR42","doi-asserted-by":"publisher","unstructured":"Nairz J, Messner A, Kiechl SJ, Winder B, Hochmayr C, Egger AE, et al. Determinants of non-alcoholic fatty liver disease in young people: maternal, neonatal, and adolescent factors. PLoS One. 2024;19:e0298800. https:\/\/doi.org\/10.1371\/journal.pone.0298800.","DOI":"10.1371\/journal.pone.0298800"},{"key":"698_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000437054","volume":"84","author":"LM Breij","year":"2015","unstructured":"Breij LM, Kerkhof GF, Hokken-Koelega ACS. Risk for nonalcoholic fatty liver disease in young adults born preterm. Horm Res Paediatr. 2015;84:199\u2013205. https:\/\/doi.org\/10.1159\/000437054.","journal-title":"Horm Res Paediatr"},{"key":"698_CR44","doi-asserted-by":"publisher","unstructured":"McCurdy CE, Bishop JM, Williams SM, Grayson BE, Smith MS, Friedman JE, et al. Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. J Clin Invest. 2009;JCI32661. https:\/\/doi.org\/10.1172\/JCI32661.","DOI":"10.1172\/JCI32661"},{"key":"698_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1158089","volume":"14","author":"B Harmanc\u0131o\u011flu","year":"2023","unstructured":"Harmanc\u0131o\u011flu B, Kabaran S. Maternal high fat diets: impacts on offspring obesity and epigenetic hypothalamic programming. Front Genet. 2023;14:1158089. https:\/\/doi.org\/10.3389\/fgene.2023.1158089.","journal-title":"Front Genet"},{"key":"698_CR46","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.2337\/db14-0276","volume":"63","author":"SR Thorn","year":"2014","unstructured":"Thorn SR, Baquero KC, Newsom SA, El Kasmi KC, Bergman BC, Shulman GI, et al. Early life exposure to maternal insulin resistance has persistent effects on hepatic NAFLD in juvenile nonhuman primates. Diabetes. 2014;63:2702\u201313. https:\/\/doi.org\/10.2337\/db14-0276.","journal-title":"Diabetes"},{"key":"698_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrgastro.2016.160","volume":"14","author":"SR Wesolowski","year":"2017","unstructured":"Wesolowski SR, Kasmi KCE, Jonscher KR, Friedman JE. Developmental origins of NAFLD: a womb with a clue. Nat Rev Gastroenterol Hepatol. 2017;14:81\u201396. https:\/\/doi.org\/10.1038\/nrgastro.2016.160.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"698_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jnutbio.2017.10.004","volume":"54","author":"Z Cheng","year":"2018","unstructured":"Cheng Z, Zheng L, Almeida FA. Epigenetic reprogramming in metabolic disorders: nutritional factors and beyond. J Nutr Biochem. 2018;54:1\u201310. https:\/\/doi.org\/10.1016\/j.jnutbio.2017.10.004.","journal-title":"J Nutr Biochem"},{"key":"698_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12902","volume":"17","author":"CC Cohen","year":"2022","unstructured":"Cohen CC, Francis EC, Perng W, Sauder KA, Scherzinger A, Sundaram SS, et al. Exposure to maternal fuels during pregnancy and offspring hepatic fat in early childhood: the healthy start study. Pediatr Obes. 2022;17:e12902. https:\/\/doi.org\/10.1111\/ijpo.12902.","journal-title":"Pediatr Obes"},{"key":"698_CR50","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1210\/en.2012-1683","volume":"154","author":"Y-M Su","year":"2013","unstructured":"Su Y-M, Lv G-R, Xie J-X, Wang Z-H, Lin H-T. Maternal hypoxia increases the susceptibility of adult rat male offspring to high-fat diet-induced nonalcoholic fatty liver disease. Endocrinology. 2013;154:4377\u201387. https:\/\/doi.org\/10.1210\/en.2012-1683.","journal-title":"Endocrinology"},{"key":"698_CR51","doi-asserted-by":"publisher","first-page":"945768","DOI":"10.3389\/fcdhc.2022.945768","volume":"3","author":"KY Sugino","year":"2022","unstructured":"Sugino KY, Mandala A, Janssen RC, Gurung S, Trammell M, Day MW, et al. Western diet-induced shifts in the maternal microbiome are associated with altered microRNA expression in baboon placenta and fetal liver. Front Clin Diabetes Healthc. 2022;3:945768. https:\/\/doi.org\/10.3389\/fcdhc.2022.945768.","journal-title":"Front Clin Diabetes Healthc"},{"key":"698_CR52","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1152\/ajpendo.00076.2013","volume":"305","author":"J Saben","year":"2013","unstructured":"Saben J, Zhong Y, Gomez-Acevedo H, Thakali KM, Borengasser SJ, Andres A, et al. Early growth response protein-1 mediates lipotoxicity-associated placental inflammation: role in maternal obesity. Am J Physiol-Endocrinol Metab. 2013;305:E1\u201314. https:\/\/doi.org\/10.1152\/ajpendo.00076.2013.","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"698_CR53","doi-asserted-by":"publisher","first-page":"R1569","DOI":"10.1152\/ajpregu.00385.2015","volume":"309","author":"P D\u00edaz","year":"2015","unstructured":"D\u00edaz P, Harris J, Rosario FJ, Powell TL, Jansson T. Increased placental fatty acid transporter 6 and binding protein 3 expression and fetal liver lipid accumulation in a mouse model of obesity in pregnancy. Am J Physiol Regul Integr Comp Physiol. 2015;309:R1569-77. https:\/\/doi.org\/10.1152\/ajpregu.00385.2015.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"698_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94200","volume":"2","author":"PR Baker","year":"2017","unstructured":"Baker PR, Patinkin Z, Shapiro ALB, De La Houssaye BA, Woontner M, Boyle KE, et al. Maternal obesity and increased neonatal adiposity correspond with altered infant mesenchymal stem cell metabolism. JCI Insight. 2017;2:e94200. https:\/\/doi.org\/10.1172\/jci.insight.94200.","journal-title":"JCI Insight"},{"key":"698_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17588-4","volume":"7","author":"PR Baker","year":"2017","unstructured":"Baker PR, Patinkin ZW, Shapiro ALB, De La Houssaye BA, Janssen RC, Vanderlinden LA, et al. Altered gene expression and metabolism in fetal umbilical cord mesenchymal stem cells correspond with differences in 5-month-old infant adiposity gain. Sci Rep. 2017;7:18095. https:\/\/doi.org\/10.1038\/s41598-017-17588-4.","journal-title":"Sci Rep"},{"key":"698_CR56","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","volume":"36","author":"P Horn","year":"2024","unstructured":"Horn P, Tacke F. Metabolic reprogramming in liver fibrosis. Cell Metab. 2024;36:1439\u201355. https:\/\/doi.org\/10.1016\/j.cmet.2024.05.003.","journal-title":"Cell Metab"},{"key":"698_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89690-x","volume":"15","author":"F Amiri","year":"2025","unstructured":"Amiri F, Moludi J, Jouybari TA, Ghasemi M, Sharifi M, Mahaki B, et al. Relationship between dietary inflammatory index and metabolic dysfunction associated steatotic liver disease in children. Sci Rep. 2025;15:5081. https:\/\/doi.org\/10.1038\/s41598-025-89690-x.","journal-title":"Sci Rep"},{"key":"698_CR58","doi-asserted-by":"publisher","unstructured":"Kravchuk S, Bychkov M, Kozyk M, Strubchevska O, Kozyk A. Managing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the Digital Era: Overcoming Barriers to Lifestyle Change. Cureus [Internet]. 2025 [cited 2025 Aug 18]; https:\/\/doi.org\/10.7759\/cureus.84803","DOI":"10.7759\/cureus.84803"},{"key":"698_CR59","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1542\/peds.2006-1212","volume":"118","author":"JB Schwimmer","year":"2006","unstructured":"Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388\u201393. https:\/\/doi.org\/10.1542\/peds.2006-1212.","journal-title":"Pediatrics"},{"key":"698_CR60","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/apt.12518","volume":"38","author":"JB Schwimmer","year":"2013","unstructured":"Schwimmer JB, Newton KP, Awai HI, Choi LJ, Garcia MA, Ellis LL, et al. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38:1267\u201377. https:\/\/doi.org\/10.1111\/apt.12518.","journal-title":"Aliment Pharmacol Ther"},{"key":"698_CR61","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/jpn3.12068","volume":"78","author":"L Kalveram","year":"2024","unstructured":"Kalveram L, Baumann U, De Bruyne R, Draijer L, Janczyk W, Kelly D, et al. Noninvasive scores are poorly predictive of histological fibrosis in paediatric fatty liver disease. J Pediatr Gastroenterol Nutr. 2024;78:27\u201335. https:\/\/doi.org\/10.1002\/jpn3.12068.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"698_CR62","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1097\/HEP.0000000000000644","volume":"79","author":"A Wang","year":"2024","unstructured":"Wang A, Blackford AL, Behling C, Wilson LA, Newton KP, Xanthakos SA, et al. Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease. Hepatology. 2024;79:1381\u201392. https:\/\/doi.org\/10.1097\/HEP.0000000000000644.","journal-title":"Hepatology"},{"key":"698_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-93082-6","volume":"15","author":"BC Czapla","year":"2025","unstructured":"Czapla BC, Dalvi A, Hu J, Moran IJ, Wijarnpreecha K, Chen VL. Physical activity, diet, and social determinants of health associate with health related quality of life and fibrosis in MASLD. Sci Rep. 2025;15:7976. https:\/\/doi.org\/10.1038\/s41598-025-93082-6.","journal-title":"Sci Rep"},{"key":"698_CR64","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.4162\/nrp.2023.17.6.1185","volume":"17","author":"H Lee","year":"2023","unstructured":"Lee H, Oldewage-Theron W, Lyford C, Shine S. Nutrition and health challenges among low-income families of young children in the post COVID-19 era: a qualitative study. Nutr Res Pract. 2023;17:1185. https:\/\/doi.org\/10.4162\/nrp.2023.17.6.1185.","journal-title":"Nutr Res Pract"},{"key":"698_CR65","doi-asserted-by":"publisher","unstructured":"Lam TBN, Goyal NP, Newton KP, Schwimmer JB, Reply. The PNPLA3 paradox\u2014Does genotype modify the clinical utility of the MASLD framework in children? Hepatology [Internet]. 2026 [cited 2026 Feb 17]; https:\/\/doi.org\/10.1097\/HEP.0000000000001674","DOI":"10.1097\/HEP.0000000000001674"},{"key":"698_CR66","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.cgh.2017.02.030","volume":"16","author":"JA Africa","year":"2018","unstructured":"Africa JA, Behling CA, Brunt EM, Zhang N, Luo Y, Wells A, et al. In children with nonalcoholic fatty liver disease, zone 1 steatosis is associated with advanced fibrosis. Clin Gastroenterol Hepatol. 2018;16:438-446.e1. https:\/\/doi.org\/10.1016\/j.cgh.2017.02.030.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"698_CR67","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3345\/cep.2022.00367","volume":"66","author":"E Ozdogan","year":"2023","unstructured":"Ozdogan E, Arikan C. Liver fibrosis in children: a comprehensive review of mechanisms, diagnosis, and therapy. Clin Exp Pediatr. 2023;66:110\u201324. https:\/\/doi.org\/10.3345\/cep.2022.00367.","journal-title":"Clin Exp Pediatr"},{"key":"698_CR68","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/hep.20842","volume":"42","author":"JB Schwimmer","year":"2005","unstructured":"Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et al. Histopathology of Pediatric Nonalcoholic Fatty Liver Disease * #. Hepatology. 2005;42:641\u20139. https:\/\/doi.org\/10.1002\/hep.20842.","journal-title":"Hepatology"},{"key":"698_CR69","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1053\/j.gastro.2016.08.027","volume":"151","author":"JB Schwimmer","year":"2016","unstructured":"Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos SA, Kohli R, et al. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. Gastroenterology. 2016;151:1141\u2013e11549. https:\/\/doi.org\/10.1053\/j.gastro.2016.08.027.","journal-title":"Gastroenterology"},{"key":"698_CR70","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41467-024-45751-9","volume":"15","author":"SWS Kang","year":"2024","unstructured":"Kang SWS, Cunningham RP, Miller CB, Brown LA, Cultraro CM, Harned A, et al. A spatial map of hepatic mitochondria uncovers functional heterogeneity shaped by nutrient-sensing signaling. Nat Commun. 2024;15:1799. https:\/\/doi.org\/10.1038\/s41467-024-45751-9.","journal-title":"Nat Commun"},{"key":"698_CR71","doi-asserted-by":"publisher","first-page":"12977","DOI":"10.1038\/ncomms12977","volume":"7","author":"N Kubota","year":"2016","unstructured":"Kubota N, Kubota T, Kajiwara E, Iwamura T, Kumagai H, Watanabe T, et al. Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity. Nat Commun. 2016;7:12977. https:\/\/doi.org\/10.1038\/ncomms12977.","journal-title":"Nat Commun"},{"key":"698_CR72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1126\/science.abi9547","volume":"377","author":"AL Cangelosi","year":"2022","unstructured":"Cangelosi AL, Puszynska AM, Roberts JM, Armani A, Nguyen TP, Spinelli JB, et al. Zonated leucine sensing by Sestrin-mTORC1 in the liver controls the response to dietary leucine. Science. 2022;377:47\u201356. https:\/\/doi.org\/10.1126\/science.abi9547.","journal-title":"Science"},{"key":"698_CR73","doi-asserted-by":"publisher","first-page":"101815","DOI":"10.1016\/j.molmet.2023.101815","volume":"78","author":"MM Zelows","year":"2023","unstructured":"Zelows MM, Cady C, Dharanipragada N, Mead AE, Kipp ZA, Bates EA, et al. Loss of carnitine palmitoyltransferase 1a reduces docosahexaenoic acid-containing phospholipids and drives sexually dimorphic liver disease in mice. Mol Metab. 2023;78:101815. https:\/\/doi.org\/10.1016\/j.molmet.2023.101815.","journal-title":"Mol Metab"},{"key":"698_CR74","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3345\/cep.2025.00157","volume":"68","author":"A Agrawal","year":"2025","unstructured":"Agrawal A, Samanta A. Metabolic dysfunction-associated steatotic liver disease in children: a practical update based on Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition (ISPGHAN) 2024 guidelines. Clin Exp Pediatr. 2025;68:546\u201350. https:\/\/doi.org\/10.3345\/cep.2025.00157.","journal-title":"Clin Exp Pediatr"},{"key":"698_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17060947","volume":"17","author":"J Temple","year":"2016","unstructured":"Temple J, Cordero P, Li J, Nguyen V, Oben J. A guide to non-alcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci. 2016;17:947. https:\/\/doi.org\/10.3390\/ijms17060947.","journal-title":"Int J Mol Sci"},{"key":"698_CR76","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5152\/tjg.2019.19367","volume":"31","author":"Y Y\u0131ld\u0131z","year":"2020","unstructured":"Y\u0131ld\u0131z Y, Sivri HS. Inborn errors of metabolism in the differential diagnosis of fatty liver disease. Turk J Gastroenterol. 2020;31:3\u201316. https:\/\/doi.org\/10.5152\/tjg.2019.19367.","journal-title":"Turk J Gastroenterol"},{"key":"698_CR77","doi-asserted-by":"publisher","first-page":"251","DOI":"10.5223\/pghn.2016.19.4.251","volume":"19","author":"YK Koh","year":"2016","unstructured":"Koh YK, Lee JH, Kim EY, Moon KR. Acanthosis nigricans as a clinical predictor of insulin resistance in obese children. Pediatr Gastroenterol Hepatol Nutr. 2016;19:251. https:\/\/doi.org\/10.5223\/pghn.2016.19.4.251.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"698_CR78","doi-asserted-by":"publisher","first-page":"42","DOI":"10.21037\/pm-21-70","volume":"5","author":"S Pollock","year":"2022","unstructured":"Pollock S, Swamy MR, Tremblay ES, Shen L. Acanthosis nigricans in the pediatric population: a narrative review of the current approach to management in primary care. Pediatr Med (Kaunas). 2022;5:42\u201342. https:\/\/doi.org\/10.21037\/pm-21-70.","journal-title":"Pediatr Med (Kaunas)"},{"key":"698_CR79","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.21170","volume":"8","author":"E M\u00fcnte","year":"2025","unstructured":"M\u00fcnte E, Zhang X, Khurana A, Hartmann P. Prevalence of extremely severe obesity and metabolic dysfunction among US children and adolescents. JAMA Netw Open. 2025;8:e2521170. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.21170.","journal-title":"JAMA Netw Open"},{"key":"698_CR80","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12933-025-02824-3","volume":"24","author":"E Han","year":"2025","unstructured":"Han E, Han K-D, Lee Y, Kim K-S, Hong S, Park JH, et al. Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality. Cardiovasc Diabetol. 2025;24:289. https:\/\/doi.org\/10.1186\/s12933-025-02824-3.","journal-title":"Cardiovasc Diabetol"},{"key":"698_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101419","volume":"7","author":"K Song","year":"2025","unstructured":"Song K, Lee E, Lee HS, Youn YH, Baik SJ, Shin HJ, et al. Identification of pediatric MASLD using insulin resistance indices. JHEP Rep. 2025;7:101419. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101419.","journal-title":"JHEP Rep"},{"key":"698_CR82","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/jpn3.12272","volume":"79","author":"M Mouzaki","year":"2024","unstructured":"Mouzaki M, Yates KP, Arce-Clachar AC, Behling C, Blondet NM, Fishbein MH, et al. Renal impairment is prevalent in pediatric NAFLD\/MASLD and associated with disease severity. J Pediatr Gastroenterol Nutr. 2024;79:238\u201349. https:\/\/doi.org\/10.1002\/jpn3.12272.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"698_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2025.10.001","author":"M Esposito","year":"2025","unstructured":"Esposito M, Rimauro I, Frattolillo V, Forcina G, Marzuillo P, Miraglia Del Giudice E, et al. MASLD in childhood as a multisystem health challenge beyond the liver. Trends Endocrinol Metab. 2025. https:\/\/doi.org\/10.1016\/j.tem.2025.10.001. S104327602500222X.","journal-title":"Trends Endocrinol Metab"},{"key":"698_CR84","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1212\/WNL.0000000000002498","volume":"86","author":"SW Seo","year":"2016","unstructured":"Seo SW, Gottesman RF, Clark JM, Hernaez R, Chang Y, Kim C, et al. Nonalcoholic fatty liver disease is associated with cognitive function in adults. Neurology. 2016;86:1136\u201342. https:\/\/doi.org\/10.1212\/WNL.0000000000002498.","journal-title":"Neurology"},{"key":"698_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/nu17243871","volume":"17","author":"JK DiStefano","year":"2025","unstructured":"DiStefano JK. Early-life nutritional determinants of pediatric MASLD. Nutrients. 2025;17:3871. https:\/\/doi.org\/10.3390\/nu17243871.","journal-title":"Nutrients"},{"key":"698_CR86","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3345\/cep.2022.01312","volume":"66","author":"K Song","year":"2023","unstructured":"Song K, Kim H-S, Chae HW. Nonalcoholic fatty liver disease and insulin resistance in children. Clin Exp Pediatr. 2023;66:512\u20139. https:\/\/doi.org\/10.3345\/cep.2022.01312.","journal-title":"Clin Exp Pediatr"},{"key":"698_CR87","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/jcm14020428","volume":"14","author":"E Michalopoulou","year":"2025","unstructured":"Michalopoulou E, Thymis J, Lampsas S, Pavlidis G, Katogiannis K, Vlachomitros D, et al. The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment. J Clin Med. 2025;14:428. https:\/\/doi.org\/10.3390\/jcm14020428.","journal-title":"J Clin Med"},{"key":"698_CR88","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/MPG.0000000000003371","volume":"74","author":"T Yodoshi","year":"2022","unstructured":"Yodoshi T, Orkin S, Trout AT, Arce-Clachar AC, Bramlage K, Liu C, et al. Non\u2010Invasive Approaches to Estimate Liver Steatosis and Stiffness in Children With Non\u2010Alcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2022;74:495\u2013502. https:\/\/doi.org\/10.1097\/MPG.0000000000003371.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"698_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.784221","volume":"9","author":"S Jia","year":"2022","unstructured":"Jia S, Zhao Y, Liu J, Guo X, Chen M, Zhou S, et al. Magnetic resonance imaging-proton density fat fraction vs. transient elastography-controlled attenuation parameter in diagnosing non-alcoholic fatty liver disease in children and adolescents: a meta-analysis of diagnostic accuracy. Front Pediatr. 2022;9:784221. https:\/\/doi.org\/10.3389\/fped.2021.784221.","journal-title":"Front Pediatr"},{"key":"698_CR90","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/chi.2022.0136","volume":"19","author":"PV Alves","year":"2023","unstructured":"Alves PV, Trout VT, Dewit A, Mouzaki M, Arce-Clachar M, Bramlage ACS. Clinical performance of transient elastography with comparison to quantitative magnetic resonance imaging, ultrasound, and biopsy in children and adolescents with known or suspected fatty liver disease. Child Obes. 2023;19:461\u20139. https:\/\/doi.org\/10.1089\/chi.2022.0136.","journal-title":"Child Obes"},{"key":"698_CR91","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12519-023-00704-y","volume":"20","author":"Z-W Qin","year":"2024","unstructured":"Qin Z-W, Ren Q-N, Zhang H-X, Liu Y-R, Huang K, Wu W, et al. Development and validation of a novel non-invasive test for diagnosing nonalcoholic fatty liver disease in Chinese children. World J Pediatr. 2024;20:413\u201321. https:\/\/doi.org\/10.1007\/s12519-023-00704-y.","journal-title":"World J Pediatr"},{"key":"698_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101150","volume":"49","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang Y, Xing Y, Wolters M, Shi D, Zhang P, et al. Establish a noninvasive model to screen metabolic dysfunction-associated steatotic liver disease in children aged 6\u201314 years in China and its applications in high-obesity-risk countries and regions. Lancet Reg Health-West Pac. 2024;49:101150. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101150.","journal-title":"Lancet Reg Health-West Pac"},{"key":"698_CR93","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jceh.2020.11.004","volume":"11","author":"GA Rodge","year":"2021","unstructured":"Rodge GA, Goenka MK, Goenka U, Afzalpurkar S, Shah BB. Quantification of liver fat by MRI-PDFF imaging in patients with suspected non-alcoholic fatty liver disease and its correlation with metabolic syndrome, liver function test and ultrasonography. J Clin Exp Hepatol. 2021;11:586\u201391. https:\/\/doi.org\/10.1016\/j.jceh.2020.11.004.","journal-title":"J Clin Exp Hepatol"},{"key":"698_CR94","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1002\/hep4.1983","volume":"6","author":"A Chaidez","year":"2022","unstructured":"Chaidez A, Pan Z, Sundaram SS, Boster J, Lovell M, Sokol RJ, et al. The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan\u2013aspartate aminotransferase to predict severity of liver disease in children. Hepatol Commun. 2022;6:3015\u201323. https:\/\/doi.org\/10.1002\/hep4.1983.","journal-title":"Hepatol Commun"},{"key":"698_CR95","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1097\/HEP.0000000000001016","volume":"81","author":"S Lefere","year":"2025","unstructured":"Lefere S, Mosca A, Hudert C, Dupont E, Fitzpatrick E, Kyrana E, et al. Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD. Hepatology. 2025;81:1276\u201387. https:\/\/doi.org\/10.1097\/HEP.0000000000001016.","journal-title":"Hepatology"},{"key":"698_CR96","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","volume":"64","author":"MB Vos","year":"2017","unstructured":"Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64:319\u201334. https:\/\/doi.org\/10.1097\/MPG.0000000000001482.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"698_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101167","volume":"50","author":"V Ajmera","year":"2021","unstructured":"Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab. 2021;50:101167. https:\/\/doi.org\/10.1016\/j.molmet.2021.101167.","journal-title":"Mol Metab"},{"key":"698_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/children5060064","volume":"5","author":"I Arsik","year":"2018","unstructured":"Arsik I, Frediani JK, Frezza D, Chen W, Ayer T, Keskinocak P, et al. Alanine aminotransferase as a monitoring biomarker in children with nonalcoholic fatty liver disease: a secondary analysis using TONIC trial data. Children. 2018;5:64. https:\/\/doi.org\/10.3390\/children5060064.","journal-title":"Children"},{"key":"698_CR99","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/jpn3.12040","volume":"78","author":"L Aitokari","year":"2024","unstructured":"Aitokari L, Lahti S, Kivel\u00e4 L, Riekki H, Hiltunen P, Vuorela N, et al. Alanine aminotransferase cutoffs for the pediatric fatty liver disease: Major impact of the reference population. J Pediatr Gastroenterol Nutr. 2024;78:488\u201396. https:\/\/doi.org\/10.1002\/jpn3.12040.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"698_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2025-001895","volume":"12","author":"L Luo","year":"2025","unstructured":"Luo L, Shao C, Teng L, Zhuo S, Dong Z, Wang W, et al. Liver fibrosis with persistently normal alanine transaminase levels exhibits a distinct treatment response in MASLD. BMJ Open Gastroenterol. 2025;12:e001895. https:\/\/doi.org\/10.1136\/bmjgast-2025-001895.","journal-title":"BMJ Open Gastroenterol"},{"key":"698_CR101","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1097\/JOM.0b013e31822cfd68","volume":"53","author":"M Cave","year":"2011","unstructured":"Cave M, Falkner KC, Henry L, Costello B, Gregory B, McClain CJ. Serum cytokeratin 18 and cytokine elevations suggest a high prevalence of occupational liver disease in highly exposed elastomer\/polymer workers. J Occup Environ Med. 2011;53:1128\u201333. https:\/\/doi.org\/10.1097\/JOM.0b013e31822cfd68.","journal-title":"J Occup Environ Med"},{"key":"698_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.05.010","author":"R Vuppalanchi","year":"2014","unstructured":"Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, et al. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014. https:\/\/doi.org\/10.1016\/j.cgh.2014.05.010.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"698_CR103","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/MPG.0b013e31817e2bfb","volume":"47","author":"MB Vos","year":"2008","unstructured":"Vos MB, Barve S, Joshi-Barve S, Carew JD, Whitington PF, McClain CJ. Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2008;47:481\u20135. https:\/\/doi.org\/10.1097\/MPG.0b013e31817e2bfb.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"698_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.168","author":"AE Feldstein","year":"2013","unstructured":"Feldstein AE, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol. 2013. https:\/\/doi.org\/10.1038\/ajg.2013.168.","journal-title":"Am J Gastroenterol"},{"key":"698_CR105","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3181e376be","author":"E Fitzpatrick","year":"2010","unstructured":"Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, deBruyne R, Dhawan A. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr. 2010. https:\/\/doi.org\/10.1097\/MPG.0b013e3181e376be.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"698_CR106","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/j.1365-2362.2010.02338.x","volume":"40","author":"Y Yilmaz","year":"2010","unstructured":"Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest. 2010;40:887\u201392. https:\/\/doi.org\/10.1111\/j.1365-2362.2010.02338.x.","journal-title":"Eur J Clin Invest"},{"key":"698_CR107","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5152\/tjg.2025.24760","volume":"36","author":"M Keskin","year":"2025","unstructured":"Keskin M, Aysegul Arsoy H, Kara O, et al. Metabolic and hepatic profiles of non-obese and obese metabolic dysfunction-associated steatotic liver disease in adolescents: the role of FibroScan parameters, fibroblast growth factor-21, and cytokeratin-18. Turk J Gastroenterol. 2025;36:152\u201361. https:\/\/doi.org\/10.5152\/tjg.2025.24760.","journal-title":"Turk J Gastroenterol"},{"key":"698_CR108","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1210\/jc.2012-1221","volume":"97","author":"T Reinehr","year":"2012","unstructured":"Reinehr T, Woelfle J, Wunsch R, Roth CL. Fibroblast Growth Factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab. 2012;97:2143\u201350. https:\/\/doi.org\/10.1210\/jc.2012-1221.","journal-title":"J Clin Endocrinol Metab"},{"key":"698_CR109","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1250","author":"C Giannini","year":"2013","unstructured":"Giannini C, Feldstein AE, Santoro N, Kim G, Kursawe R, Pierpont B, et al. Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab. 2013. https:\/\/doi.org\/10.1210\/jc.2013-1250.","journal-title":"J Clin Endocrinol Metab"},{"key":"698_CR110","doi-asserted-by":"publisher","unstructured":"Alisi A, Ceccarelli S, Panera N, Prono F, Petrini S, De Stefanis C, et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS One. 2013;8:e67160. https:\/\/doi.org\/10.1371\/journal.pone.0067160.","DOI":"10.1371\/journal.pone.0067160"},{"key":"698_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00420","volume":"7","author":"M-C Hua","year":"2019","unstructured":"Hua M-C, Huang J-L, Hu C-C, Yao T-C, Lai M-W. Including fibroblast growth factor-21 in combined biomarker panels improves predictions of liver steatosis severity in children. Front Pediatr. 2019;420. https:\/\/doi.org\/10.3389\/fped.2019.00420.","journal-title":"Front Pediatr"},{"key":"698_CR112","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001357","author":"JB Schwimmer","year":"2025","unstructured":"Schwimmer JB, Thai NQN, Noon SL, Ugalde-Nicalo P, Anderson SR, Chun LF, et al. Long-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study. Hepatol [Internet]. 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001357. [cited 2025 Aug 20].","journal-title":"Hepatol [Internet]"},{"key":"698_CR113","doi-asserted-by":"publisher","first-page":"goaf056","DOI":"10.1093\/gastro\/goaf056","volume":"13","author":"W Li","year":"2025","unstructured":"Li W, Jiang L, Li M, Lin C, Zhu L, Zhao B, et al. Metabolic dysfunction-associated steatotic liver disease is associated with the risk of severe liver fibrosis in pediatric population. Gastroenterol Rep. 2025;13:goaf056. https:\/\/doi.org\/10.1093\/gastro\/goaf056.","journal-title":"Gastroenterol Rep"},{"key":"698_CR114","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12072-023-10550-9","volume":"17","author":"W-L Chan","year":"2023","unstructured":"Chan W-L, Chong S-E, Chang F, Lai L-L, Chuah K-H, Nik Mustapha NR, et al. Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy. Hepatol Int. 2023;17:870\u201381. https:\/\/doi.org\/10.1007\/s12072-023-10550-9.","journal-title":"Hepatol Int"},{"key":"698_CR115","doi-asserted-by":"publisher","first-page":"e80163","DOI":"10.2196\/80163","volume":"14","author":"Z Mao","year":"2026","unstructured":"Mao Z, Chen J. Comprehensive pediatric health risk stratification using an AI-driven framework in children aged 2 to 8 years: design and validation study. JMIR Med Inform. 2026;14:e80163\u2013e80163. https:\/\/doi.org\/10.2196\/80163.","journal-title":"JMIR Med Inform"},{"key":"698_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.613594","volume":"8","author":"RR Das","year":"2021","unstructured":"Das RR, Mangaraj M, Nayak S, Satapathy AK, Mahapatro S, Goyal JP. Prevalence of insulin resistance in urban Indian school children who are overweight\/obese: a cross-sectional study. Front Med. 2021;8:613594. https:\/\/doi.org\/10.3389\/fmed.2021.613594.","journal-title":"Front Med"},{"key":"698_CR117","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41591-024-03279-x","volume":"31","author":"Y Huang","year":"2025","unstructured":"Huang Y, Sulek K, Stinson SE, Holm LA, Kim M, Trost K, et al. Lipid profiling identifies modifiable signatures of cardiometabolic risk in children and adolescents with obesity. Nat Med. 2025;31:294\u2013305. https:\/\/doi.org\/10.1038\/s41591-024-03279-x.","journal-title":"Nat Med"},{"key":"698_CR118","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/metabo15050287","volume":"15","author":"S Accacha","year":"2025","unstructured":"Accacha S, Barillas-Cerritos J, Srivastava A, Ross F, Drewes W, Gulkarov S, et al. From Childhood Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Hyperlipidemia Through Oxidative Stress During Childhood. Metabolites. 2025;15:287. https:\/\/doi.org\/10.3390\/metabo15050287.","journal-title":"Metabolites"},{"key":"698_CR119","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cgh.2022.05.028","volume":"21","author":"KP Newton","year":"2023","unstructured":"Newton KP, Wilson LA, Crimmins NA, Fishbein MH, Molleston JP, Xanthakos SA, et al. Incidence of Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2023;21:1261\u201370. https:\/\/doi.org\/10.1016\/j.cgh.2022.05.028.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"698_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11192696","volume":"11","author":"A Solomon","year":"2023","unstructured":"Solomon A, Negrea MO, Cip\u0103ian CR, Boicean A, Mihaila R, Rezi C, et al. Interactions between metabolic syndrome, MASLD, and arterial stiffening: a single-center cross-sectional study. Healthcare. 2023;11:2696. https:\/\/doi.org\/10.3390\/healthcare11192696.","journal-title":"Healthcare"},{"key":"698_CR121","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00431-024-05848-1","volume":"184","author":"A-SR Stroes","year":"2024","unstructured":"Stroes A-SR, Vos M, Benninga MA, Koot BGP. Pediatric MASLD: current understanding and practical approach. Eur J Pediatr. 2024;184:29. https:\/\/doi.org\/10.1007\/s00431-024-05848-1.","journal-title":"Eur J Pediatr"},{"key":"698_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/nu12113310","volume":"12","author":"FJ Rup\u00e9rez","year":"2020","unstructured":"Rup\u00e9rez FJ, Martos-Moreno G\u00c1, Chamoso-S\u00e1nchez D, Barbas C, Argente J. Insulin resistance in obese children: what can metabolomics and adipokine modelling contribute? Nutrients. 2020;12:3310. https:\/\/doi.org\/10.3390\/nu12113310.","journal-title":"Nutrients"},{"key":"698_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/nu17071158","volume":"17","author":"S Matsuda","year":"2025","unstructured":"Matsuda S, Nakashima M, Fukumoto A, Suga N. N6-methyladenosine modification in the metabolic dysfunction-associated steatotic liver disease. Nutrients. 2025;17:1158. https:\/\/doi.org\/10.3390\/nu17071158.","journal-title":"Nutrients"},{"key":"698_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040866","volume":"13","author":"M Reguero","year":"2021","unstructured":"Reguero M, G\u00f3mez De Cedr\u00f3n M, Wagner S, Reglero G, Quintela JC, Ram\u00edrez De Molina A. Precision nutrition to activate thermogenesis as a complementary approach to target obesity and associated-metabolic-disorders. Cancers. 2021;13:866. https:\/\/doi.org\/10.3390\/cancers13040866.","journal-title":"Cancers"},{"key":"698_CR125","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01749-1","volume":"25","author":"AM Mostafa","year":"2025","unstructured":"Mostafa AM, Fouad Y, Gaber Y, Alem SA, Pan Z, Eslam M. Differential risk factors of fibrosis between lean and obese MAFLD. Clin Exp Med. 2025;25:211. https:\/\/doi.org\/10.1007\/s10238-025-01749-1.","journal-title":"Clin Exp Med"},{"key":"698_CR126","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hep.22336","volume":"48","author":"V Nobili","year":"2008","unstructured":"Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial\u2020. Hepatology. 2008;48:119\u201328. https:\/\/doi.org\/10.1002\/hep.22336.","journal-title":"Hepatology"},{"key":"698_CR127","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10620-016-4126-1","volume":"61","author":"JA Africa","year":"2016","unstructured":"Africa JA, Newton KP, Schwimmer JB. Lifestyle interventions including nutrition, exercise, and supplements for nonalcoholic fatty liver disease in children. Dig Dis Sci. 2016;61:1375\u201386. https:\/\/doi.org\/10.1007\/s10620-016-4126-1.","journal-title":"Dig Dis Sci"},{"key":"698_CR128","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/MPG.0000000000002527","volume":"70","author":"S Orkin","year":"2020","unstructured":"Orkin S, Brokamp C, Yodoshi T, Trout AT, Liu C, Meryum S, et al. Community Socioeconomic Deprivation and Nonalcoholic Fatty Liver Disease Severity. J Pediatr Gastroenterol Nutr. 2020;70:364\u201370. https:\/\/doi.org\/10.1097\/MPG.0000000000002527.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"698_CR129","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","volume":"59","author":"V-S Wong","year":"2013","unstructured":"Wong V-S, Chan R-M, Wong G-H, Cheung B-K, Chu W-W, Yeung D-W, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2013;59:536\u201342. https:\/\/doi.org\/10.1016\/j.jhep.2013.04.013.","journal-title":"J Hepatol"},{"key":"698_CR130","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-378.e5. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005.","journal-title":"Gastroenterology"},{"key":"698_CR131","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1053\/j.gastro.2020.07.034","volume":"159","author":"SA Xanthakos","year":"2020","unstructured":"Xanthakos SA, Lavine JE, Yates KP, Schwimmer JB, Molleston JP, Rosenthal P, et al. Progression of fatty liver disease in children receiving standard of care lifestyle advice. Gastroenterology. 2020;159:1731-1751.e10. https:\/\/doi.org\/10.1053\/j.gastro.2020.07.034.","journal-title":"Gastroenterology"},{"key":"698_CR132","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.cgh.2021.11.039","volume":"20","author":"S Lefere","year":"2022","unstructured":"Lefere S, Dupont E, De Guchtenaere A, Van Biervliet S, Vande Velde S, Verhelst X, et al. Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2022;20:2317\u2013e23264. https:\/\/doi.org\/10.1016\/j.cgh.2021.11.039.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"698_CR133","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/MCG.0b013e3181dd1348","volume":"45","author":"R Juluri","year":"2011","unstructured":"Juluri R, Vuppalanchi R, Olson J, \u00dcnalp A, Van Natta ML, Cummings OW, et al. Generalizability of the nonalcoholic steatohepatitis clinical research network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2011;45:55\u20138. https:\/\/doi.org\/10.1097\/MCG.0b013e3181dd1348.","journal-title":"J Clin Gastroenterol"},{"key":"698_CR134","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640","volume":"151","author":"SE Hampl","year":"2023","unstructured":"Hampl SE, Hassink SG, Skinner AC, Armstrong SC, Barlow SE, Bolling CF, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151:e2022060640. https:\/\/doi.org\/10.1542\/peds.2022-060640.","journal-title":"Pediatrics"},{"key":"698_CR135","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2105\/AJPH.2012.300865","volume":"102","author":"A Hilmers","year":"2012","unstructured":"Hilmers A, Hilmers DC, Dave J. Neighborhood disparities in access to healthy foods and their effects on environmental justice. Am J Public Health. 2012;102:1644\u201354. https:\/\/doi.org\/10.2105\/AJPH.2012.300865.","journal-title":"Am J Public Health"},{"key":"698_CR136","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1097\/PG9.0000000000000141","volume":"2","author":"T Kohut","year":"2021","unstructured":"Kohut T, Panganiban J. Liraglutide with Lifestyle Intervention in Adolescents with Overweight\/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus. JPGN Rep. 2021;2:e141. https:\/\/doi.org\/10.1097\/PG9.0000000000000141.","journal-title":"JPGN Rep"},{"key":"698_CR137","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/hep.24767","volume":"55","author":"N Alkhouri","year":"2012","unstructured":"Alkhouri N, Feldstein AE, Groszmann J, Iwakiri R, Taddei Y. The TONIC trial: a step forward in treating pediatric nonalcoholic fatty liver disease. Hepatology. 2012;55:1292\u20135. https:\/\/doi.org\/10.1002\/hep.24767.","journal-title":"Hepatology"},{"key":"698_CR138","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0009922814542481","volume":"54","author":"CK Fox","year":"2015","unstructured":"Fox CK, Marlatt KL, Rudser KD, Kelly AS. Topiramate for weight reduction in adolescents with severe obesity. Clin Pediatr (Phila). 2015;54:19\u201324. https:\/\/doi.org\/10.1177\/0009922814542481.","journal-title":"Clin Pediatr (Phila)"},{"key":"698_CR139","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/jpen.2722","volume":"49","author":"T Kohut","year":"2025","unstructured":"Kohut T, Tou A, Carr E, Xanthakos S, Arce-Clachar AC, Fawaz R, et al. Topiramate treatment of pediatric metabolic dysfunction\u2013associated steatotic liver disease: A descriptive cohort study. J Parenter Enter Nutr. 2025;49:308\u201313. https:\/\/doi.org\/10.1002\/jpen.2722.","journal-title":"J Parenter Enter Nutr"},{"key":"698_CR140","doi-asserted-by":"publisher","unstructured":"Kelly AS, Bensignor MO, Hsia DS, Shoemaker AH, Shih W, Peterson C et al. Phentermine\/Topiramate for the Treatment of Adolescent Obesity. NEJM Evid [Internet]. 2022 [cited 2025 Aug 20];1. https:\/\/doi.org\/10.1056\/EVIDoa2200014","DOI":"10.1056\/EVIDoa2200014"},{"key":"698_CR141","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1007\/s00431-023-05169-9","volume":"182","author":"N Gkiourtzis","year":"2023","unstructured":"Gkiourtzis N, Michou P, Moutafi M, Glava A, Cheirakis K, Christakopoulos A, et al. The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Pediatr. 2023;182:4795\u2013806. https:\/\/doi.org\/10.1007\/s00431-023-05169-9.","journal-title":"Eur J Pediatr"},{"key":"698_CR142","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/hep.29393","volume":"66","author":"SA Xanthakos","year":"2017","unstructured":"Xanthakos SA, Trout AT, Dillman JR. Magnetic resonance elastography assessment of fibrosis in children with NAFLD: promising but not perfect. Hepatology. 2017;66:1373\u20136. https:\/\/doi.org\/10.1002\/hep.29393.","journal-title":"Hepatology"},{"key":"698_CR143","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/hep.29596","volume":"67","author":"MS Middleton","year":"2018","unstructured":"Middleton MS, Van Natta ML, Heba ER, Alazraki A, Trout AT, Masand P, et al. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology. 2018;67:858\u201372. https:\/\/doi.org\/10.1002\/hep.29596.","journal-title":"Hepatology"},{"key":"698_CR144","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/hep4.1719","volume":"5","author":"W Ye","year":"2021","unstructured":"Ye W, Leung DH, Molleston JP, Ling SC, Murray KF, Nicholas JL, et al. Association Between Transient Elastography and Controlled Attenuated Parameter and Liver Ultrasound in Children With Cystic Fibrosis. Hepatol Commun. 2021;5:1362\u201372. https:\/\/doi.org\/10.1002\/hep4.1719.","journal-title":"Hepatol Commun"},{"key":"698_CR145","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jpeds.2021.08.012","volume":"239","author":"S Gawrieh","year":"2021","unstructured":"Gawrieh S, Harlow KE, Pike F, Yates KP, Wilson LA, Cummings OW, et al. Relationship of enhanced liver fibrosis score with pediatric nonalcoholic fatty liver disease histology and response to vitamin E or metformin. J Pediatr. 2021;239:161-167.e5. https:\/\/doi.org\/10.1016\/j.jpeds.2021.08.012.","journal-title":"J Pediatr"},{"key":"698_CR146","doi-asserted-by":"publisher","unstructured":"Huneault HE, Gent AE, Cohen CC, He Z, Jarrell ZR, Kamaleswaran R et al. Validation of a screening panel for pediatric metabolic dysfunction\u2013associated steatotic liver disease using metabolomics. Hepatol Commun [Internet]. 2024 [cited 2025 Aug 23];8. https:\/\/doi.org\/10.1097\/HC9.0000000000000375","DOI":"10.1097\/HC9.0000000000000375"},{"key":"698_CR147","doi-asserted-by":"publisher","unstructured":"Xanthakos SA, Ibrahim SH, Adams K, Kohli R, Sathya P, Sundaram S, et al. AASLD practice statement on the evaluation and management of metabolic dysfunction\u2013associated steatotic liver disease in children. Hepatology. 2025(5). https:\/\/doi.org\/10.1097\/HEP.0000000000001368.","DOI":"10.1097\/HEP.0000000000001368"},{"key":"698_CR148","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i36.112217","author":"T Yodoshi","year":"2025","unstructured":"Yodoshi T. Machine learning fibrosis score for pediatric metabolic dysfunction-associated steatotic liver disease: Promising but premature. World J Gastroenterol [Internet]. 2025. https:\/\/doi.org\/10.3748\/wjg.v31.i36.112217. [cited 2026 Feb 17];31.","journal-title":"World J Gastroenterol [Internet]"},{"key":"698_CR149","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0333581","volume":"20","author":"N Al Mazrouei","year":"2025","unstructured":"Al Mazrouei N, ElGharbawy MM, Gamal M, Emad S, Mohamed AA, Ibrahim OM, et al. Evaluating liver type fatty acid binding protein as a diagnostic and prognostic biomarker in metabolic dysfunction-associated steatotic liver disease in pediatric patients. PLOS One. 2025;20:e0333581. https:\/\/doi.org\/10.1371\/journal.pone.0333581.","journal-title":"PLOS One"},{"key":"698_CR150","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.soard.2024.08.040","volume":"21","author":"C Brichta","year":"2025","unstructured":"Brichta C, Fishbein M, Ryder JR. Outcomes of adolescent bariatric surgery: liver disease. Surg Obes Relat Dis. 2025;21:9\u201315. https:\/\/doi.org\/10.1016\/j.soard.2024.08.040.","journal-title":"Surg Obes Relat Dis"},{"key":"698_CR151","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1056\/NEJMoa1813909","volume":"380","author":"TH Inge","year":"2019","unstructured":"Inge TH, Courcoulas AP, Jenkins TM, Michalsky MP, Brandt ML, Xanthakos SA, et al. Five-year outcomes of gastric bypass in adolescents as compared with adults. N Engl J Med. 2019;380:2136\u201345. https:\/\/doi.org\/10.1056\/NEJMoa1813909.","journal-title":"N Engl J Med"},{"key":"698_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.sempedsurg.2020.150888","volume":"29","author":"A Lamoshi","year":"2020","unstructured":"Lamoshi A, Chernoguz A, Harmon CM, Helmrath M. Complications of bariatric surgery in adolescents. Semin Pediatr Surg. 2020;29:150888. https:\/\/doi.org\/10.1016\/j.sempedsurg.2020.150888.","journal-title":"Semin Pediatr Surg"},{"key":"698_CR153","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/14574969241297517","volume":"114","author":"K J\u00e4rvholm","year":"2025","unstructured":"J\u00e4rvholm K, Janson A, Henfridsson P, Neovius M, Sj\u00f6gren L, Olbers T. Metabolic and bariatric surgery for adolescents with severe obesity: benefits, risks, and specific considerations. Scand J Surg. 2025;114:95\u2013106. https:\/\/doi.org\/10.1177\/14574969241297517.","journal-title":"Scand J Surg"},{"key":"698_CR154","first-page":"407","volume":"14","author":"J Shah","year":"2018","unstructured":"Shah J, Okubote T, Alkhouri N. Overview of updated practice guidelines for pediatric nonalcoholic fatty liver disease. Gastroenterol Hepatol. 2018;14:407\u201314.","journal-title":"Gastroenterol Hepatol"},{"key":"698_CR155","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jpeds.2015.12.016","volume":"172","author":"R Kohli","year":"2016","unstructured":"Kohli R, Sunduram S, Mouzaki M, Ali S, Sathya P, Abrams S, et al. Pediatric nonalcoholic fatty liver disease: a report from the Expert Committee on Nonalcoholic Fatty Liver Disease (ECON). J Pediatr. 2016;172:9\u201313. https:\/\/doi.org\/10.1016\/j.jpeds.2015.12.016.","journal-title":"J Pediatr"},{"key":"698_CR156","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-025-00713-7","volume":"24","author":"S Jalil","year":"2025","unstructured":"Jalil S, Pagadala M, Dunn N, Blaney H, Elfeki M, Thakral N, et al. Transient elastography and Fibroscan: stethoscope of a hepatologist in today\u2019s world. Curr Hepatol Rep. 2025;24:41. https:\/\/doi.org\/10.1007\/s11901-025-00713-7.","journal-title":"Curr Hepatol Rep"},{"key":"698_CR157","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/MPG.0b013e31826f2760","volume":"56","author":"E Fitzpatrick","year":"2013","unstructured":"Fitzpatrick E, Quaglia A, Vimalesvaran S, Basso MS, Dhawan A. Transient elastography is a useful noninvasive tool for the evaluation of fibrosis in paediatric chronic liver disease. J Pediatr Gastroenterol Nutr. 2013;56:72\u20136. https:\/\/doi.org\/10.1097\/MPG.0b013e31826f2760.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"698_CR158","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11892-023-01513-3","volume":"23","author":"D Konuthula","year":"2023","unstructured":"Konuthula D, Tan MM, Burnet DL. Challenges and opportunities in diagnosis and management of cardiometabolic risk in adolescents. Curr Diab Rep. 2023;23:185\u201393. https:\/\/doi.org\/10.1007\/s11892-023-01513-3.","journal-title":"Curr Diab Rep"},{"key":"698_CR159","doi-asserted-by":"publisher","unstructured":"Evans CEL, Albar SA, Vargas-Garcia EJ, Xu F. School-Based Interventions to Reduce Obesity Risk in Children in High- and Middle-Income Countries. Adv Food Nutr Res [Internet]. Elsevier; 2015 [cited 2025 Aug 23]. pp. 29\u201377. https:\/\/doi.org\/10.1016\/bs.afnr.2015.07.003","DOI":"10.1016\/bs.afnr.2015.07.003"},{"key":"698_CR160","doi-asserted-by":"publisher","DOI":"10.3390\/nu12103166","volume":"12","author":"A Mandala","year":"2020","unstructured":"Mandala A, Janssen RC, Palle S, Short KR, Friedman JE. Pediatric non-alcoholic fatty liver disease: nutritional origins and potential molecular mechanisms. Nutrients. 2020;12:3166. https:\/\/doi.org\/10.3390\/nu12103166.","journal-title":"Nutrients"},{"key":"698_CR161","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/cld.1022","volume":"17","author":"T Kohut","year":"2021","unstructured":"Kohut T, Panganiban J. Lifestyle intervention as the primary treatment for pediatric nonalcoholic fatty liver disease. Clin Liver Dis. 2021;17:185\u201390. https:\/\/doi.org\/10.1002\/cld.1022.","journal-title":"Clin Liver Dis"},{"key":"698_CR162","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/17474124.2024.2385487","volume":"18","author":"R Righetti","year":"2024","unstructured":"Righetti R, Cinque F, Volpe MT, Sebastiani G. Integrating behavioral interventions into a holistic approach to metabolic dysfunction-associated steatotic liver disease. Expert Rev Gastroenterol Hepatol. 2024;18:303\u201313. https:\/\/doi.org\/10.1080\/17474124.2024.2385487.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"698_CR163","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jhep.2021.06.034","volume":"75","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Hartjes K, Shah U, Khalili H, Arnell H, et al. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. J Hepatol. 2021;75:1034\u201341. https:\/\/doi.org\/10.1016\/j.jhep.2021.06.034.","journal-title":"J Hepatol"},{"key":"698_CR164","doi-asserted-by":"publisher","unstructured":"Mouzaki M. Early burden, enduring risk: The alarming outcomes of pediatric MASLD. Hepatology. 2025(3). https:\/\/doi.org\/10.1097\/HEP.0000000000001362.","DOI":"10.1097\/HEP.0000000000001362"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00698-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-026-00698-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00698-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T19:02:38Z","timestamp":1773774158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-026-00698-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":164,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1007\/s13679-026-00698-4","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"22"}}